Latest Breaking News On - Two year exploratory endpoints - Page 1 : comparemela.com

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

/PRNewswire/ CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin.

Steve pascoeVifor internationalFresenius medical careDual endothelin angiotensin receptor antagonistSenior vice presidentTherapeutic area strategyEfficacy endpointsTwo year exploratory endpointsTravere therapeuticsVifor fresenius medical care renal pharmaVifor international ag csl

Vifor International AG (CSL Vifor): Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment

Steve pascoeFresenius medical careDual endothelin angiotensin receptor antagonistSenior vice presidentTherapeutic area strategyEfficacy endpointsTwo year exploratory endpointsTravere therapeuticsVifor fresenius medical care renal pharma

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with. | May 1, 2023

United statesJula inrigNaomi eichenbaumNivi nehraDeric dubeCorporate communicationsTravere therapeutics incEuropean unionExchange commission onCompany annual report on formEuropean medicines agencyTravere therapeuticsDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints

Travere Therapeutics Announces Topline Results from

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended.

United statesDeric dubeJula inrigNivi nehraNaomi eichenbaumCorporate communicationsEuropean unionTravere therapeutics incExchange commission onCompany annual report on formEuropean medicines agencyTravere therapeuticsDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNaomi eichenbaumDeric dubeJula inrigNivi nehraTravere therapeutics incEuropean medicines agencyEuropean unionExchange commission onCorporate communicationsCompany annual report on formWall streetDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints